Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Nearly 25 years of experience in analyzing hundreds of companies, especially in Asia. Deep expertise in the following sectors:
- Technology (E-commerce, SaaS, Internet)
- Consumer 
- Special Situations/Deep Value Plays
- Holdcos/Stubs
- Asian Unicorns/Private Companies

Korea/Asia, Events, IPOs

Classys (214150 KS): Beautiful Journey Continues; Record High Revenue and Operating Profit in 1Q24

Merger Between Classys and Ilooda Likely to Reduce Local Competition

Arb Spread Has Opened Today in Classys & Ilooda Merger Swap: Checking Trade Feasibility

Classys (214150 KS): Record High Quarterly Performance in Q3; 2024 to Continue to Be Radiant

Classys (214150 KS): 2023 Sales Beat Guidance to Reach Record High; Stellar Performance to Continue

Classys (214150 KS): Beautiful Growth Story Continues; No Sign of Slowing Down

Equity Capital Markets

<ul>
<li>Classys is one of the top beauty medical device companies in Korea. Classys’ main products include Shurink Universe and Volnewmer.</li>
<li>We have a positive view of Classys (214150 KS). Classys is trading at relatively reasonable valuations, considering the company's strong growth in sales and profits.</li>
<li>On 28 February, Classys announced a shareholder return amount of 38 billion won (including share cancellation of about 25 billion won and dividend payout of 13 billion won).</li>
</ul>


Classys is one of the top beauty medical device companies in Korea. Classys’ main products include Shurink Universe and Volnewmer.
We have a positive view of Classys (214150 KS). Classys is trading at relatively reasonable valuations, considering the company's strong growth in sales and profits.
On 28 February, Classys announced a shareholder return amount of 38 billion won (including share cancellation of about 25 billion won and dividend payout of 13 billion won).


Classys: One of Korea's Top Beauty Medical Device Makers + Higher Shares Cancellation and Dividends